IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 127.879
AS - Asia 8.746
EU - Europa 8.141
SA - Sud America 1.394
AF - Africa 103
Continente sconosciuto - Info sul continente non disponibili 48
OC - Oceania 21
Totale 146.332
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 127.730
SG - Singapore 3.949
CN - Cina 1.822
UA - Ucraina 1.576
HK - Hong Kong 1.495
DE - Germania 1.288
BR - Brasile 1.203
IE - Irlanda 1.080
PL - Polonia 814
IT - Italia 782
KR - Corea 703
RU - Federazione Russa 590
FR - Francia 566
GB - Regno Unito 464
FI - Finlandia 380
SE - Svezia 310
VN - Vietnam 222
IN - India 98
JP - Giappone 70
CA - Canada 69
NL - Olanda 60
AR - Argentina 56
AT - Austria 56
MX - Messico 55
BD - Bangladesh 53
ID - Indonesia 41
IQ - Iraq 40
EC - Ecuador 37
TR - Turchia 37
ES - Italia 36
EU - Europa 35
BE - Belgio 34
IR - Iran 34
ZA - Sudafrica 30
PK - Pakistan 27
CL - Cile 25
VE - Venezuela 20
AU - Australia 18
MA - Marocco 18
CO - Colombia 17
EG - Egitto 15
PY - Paraguay 15
AE - Emirati Arabi Uniti 14
SK - Slovacchia (Repubblica Slovacca) 13
UZ - Uzbekistan 13
MY - Malesia 12
KE - Kenya 11
NO - Norvegia 10
PE - Perù 10
PH - Filippine 10
RO - Romania 10
SA - Arabia Saudita 10
A2 - ???statistics.table.value.countryCode.A2??? 9
CH - Svizzera 9
CZ - Repubblica Ceca 9
TN - Tunisia 9
UY - Uruguay 9
GR - Grecia 8
KZ - Kazakistan 8
LB - Libano 8
LT - Lituania 8
AZ - Azerbaigian 7
JM - Giamaica 7
JO - Giordania 7
KG - Kirghizistan 7
NP - Nepal 7
OM - Oman 7
AL - Albania 6
CY - Cipro 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
HU - Ungheria 6
IL - Israele 6
SN - Senegal 6
CR - Costa Rica 5
LK - Sri Lanka 5
RS - Serbia 5
TW - Taiwan 5
DK - Danimarca 4
ET - Etiopia 4
HN - Honduras 4
PT - Portogallo 4
GE - Georgia 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
A1 - Anonimo 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
GI - Gibilterra 2
GT - Guatemala 2
NZ - Nuova Zelanda 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
BG - Bulgaria 1
Totale 146.320
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.476
Wilmington 33.241
Houston 30.684
Fairfield 3.702
Ann Arbor 3.125
Singapore 2.100
Chandler 2.032
Ashburn 1.734
Seattle 1.556
Hong Kong 1.482
Cambridge 1.310
Jacksonville 1.165
Dublin 1.049
Dearborn 1.007
Medford 822
Kraków 771
Beijing 746
Santa Clara 413
Lawrence 385
New York 377
Dallas 316
Rome 233
The Dalles 206
Los Angeles 205
San Diego 179
Council Bluffs 159
Moscow 149
Buffalo 125
Milan 110
Zhengzhou 109
São Paulo 104
Hangzhou 102
Mülheim 95
London 86
Norwalk 86
Menlo Park 81
Columbus 76
Ho Chi Minh City 75
Hefei 71
Mountain View 62
Redwood City 62
Verona 61
Boardman 60
Guangzhou 60
Nuremberg 59
Redondo Beach 55
Chicago 50
Hanoi 46
Shanghai 46
Rio de Janeiro 43
Nanjing 42
San Jose 41
Tokyo 41
Kunming 38
Munich 38
San Francisco 37
Warsaw 33
Brussels 31
Creede 31
Jakarta 30
Toronto 28
Brooklyn 26
Falls Church 25
Fuzhou 25
Belo Horizonte 24
Denver 23
Helsinki 23
Curitiba 22
Jinan 22
Montreal 22
Phoenix 22
San Mateo 22
Nanchang 20
Quito 20
Stockholm 20
University Park 20
Hounslow 19
Indiana 19
Mumbai 19
Chengdu 18
Seoul 18
Chennai 17
Orem 17
Porto Alegre 17
Saint Petersburg 17
Vienna 17
Atlanta 15
Baghdad 15
Bologna 15
Brasília 15
Campinas 15
Center 15
Elk Grove Village 14
Groningen 14
Johannesburg 14
Mexico City 14
Amsterdam 13
Kilburn 13
Wuhan 13
Frankfurt am Main 12
Totale 132.449
Salva come PNG Salva come JPEG
Nome #
Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers 804
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 596
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 512
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 500
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 496
A systems medicine clinical platform for understanding and managing non- communicable diseases 492
A case of SRSF2 mutation in chronic lymphocytic leukemia 487
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 485
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 483
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 481
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 474
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 470
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 467
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 467
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 466
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 463
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 463
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 461
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 458
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 457
What is the standard regimen for patients with acute promyelocytic leukemia? 457
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 454
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 452
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 452
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 451
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 450
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 450
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 450
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 449
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 449
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 448
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 447
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 446
Absence of HHV-8 DNA sequences in malignant mesothelioma 446
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 443
Clonal evolution in therapy-related neoplasms 443
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 442
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 441
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 441
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 440
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 440
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 439
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 439
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 438
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 438
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 437
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. 437
Current management of newly diagnosed acute promyelocytic leukemia 437
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 437
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 437
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 436
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 436
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 435
BCL-6 and the molecular pathogenesis of B-cell lymphoma 434
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 432
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 431
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 431
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 431
Podocalyxin is expressed in normal and leukemic monocytes 431
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 430
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 430
Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines 430
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 428
Acute myeloid leukemia developing in patients with autoimmune diseases. 428
Molecular characterization of Ph' + hybrid acute leukemia 428
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 426
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 425
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 425
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 425
High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia 425
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 425
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 425
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 424
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression 423
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 423
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 422
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 422
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 422
Panobinostat for the treatment of acute myelogenous leukemia 422
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 422
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 422
Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status 422
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia 421
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia 420
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 420
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 420
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels 419
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 419
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype 419
Current treatment of acute promyelocytic leukemia. 418
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 418
Imatinib-mesylate for all patients with hypereosinophilic syndrome? 417
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients 416
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? 416
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 415
Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma 415
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 414
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective 414
History of acute promyelocytic leukemia: a tale of endless revolution 414
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. 413
Totale 44.491
Salva come PNG Salva come JPEG
Categoria #
all - tutte 301.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 301.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.983 0 0 0 0 0 2.025 2.262 1.825 500 360 829 182
2021/20223.670 152 522 124 163 94 232 222 185 210 286 404 1.076
2022/20235.059 580 256 188 622 452 1.222 445 357 545 39 246 107
2023/20241.512 230 76 118 35 181 368 33 112 17 32 14 296
2024/20257.317 286 1.980 889 382 80 246 760 411 837 492 491 463
2025/20265.076 906 841 1.597 695 725 312 0 0 0 0 0 0
Totale 147.474